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Human immunodeficiency virus type 1 (HIV1) is the causative agent ofAIDS
(1, 2). Rapid progress in the isolation(3), cloning, and sequencingoftheentire viral
genome (4-6) has shown the remarkable propensity of HIV for genetic variation,
particularly within the envelope gene (6). Since viral envelope proteins are often
the target for neutralizing antibodies (7), this extensive variation may play an im-
portant role in the interactionbetween thevirus and the host's immune system. For
some viruses, such as influenza, rapid mutation is an important means of escape
from neutralizing antibodies (8), which results in successive waves ofinfluenza epi-
demics among previously infected populations. Forvisna virus, a sheep retrovirus,
the mutation rate is believed to be so rapid as to allow antibody escape during the
course ofasingle chronic infection (9). Ifsimilar mutants arise in humans infected
with HIV, even during the course ofmultiple rounds ofinfection, it wouldbedifficult
to imagine a vaccine antigen that could keep pace with all the possible variants and
prevent infection.
However, in spite ofthe observed rapid mutation rate, it is possible that the virus
cannot mutate at certain sites, particularly those serving essential viral functions.
For example, the CD4-binding site has been mapped to three relatively conserved
regions of gp120 (10, 11). Divergent isolates bind soluble CD4 and are inactivated
by it (12-14, and discussed in reference 15), suggesting conservation of the CD4-
binding site. Presumably, if neutralizing antibodies were directed against this site
or another site with an equally critical viral function, they would be active against
numerous clinical isolates of HIV-1, and a vaccine capable of eliciting these anti-
bodies might protect against infection by a broad spectrum ofclinical pathogens.
To study thisimportant question, we havedeveloped a sensitive new plaquingassay
for HIV-1 that divides the infection ofasuitable monolayer into aseries ofindividual
viral infection events. Like plaquing assays for other viruses (16, 17), it is highly
sensitive toneutralizingantibodies and can bereadilyadaptedto comparedivergent
HIV-1 isolates under equivalent conditions. Using this new assay, we have found
that nearly all HIV-1-infected patients make neutralizing antibodies that are group
specific, as shown by the ability to neutralize two or three divergent HIV-1 isolates
equally at each dilution of antibodies. Thus, HIV-1 isolates may be genetically di-
verse and still share a common group-specific neutralizing epitope, making them
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immunologically equivalent with respect to neutralizing antibodies. Contrary to earlier
interpretations based on genetic sequencing data, these results suggest that a suc-
cessful vaccine is possible, provided that it can elicit antibodies to the group-specific
neutralizing epitope before infection.
Materials and Methods
Cells.
￿
The adherent CD4' HeLa human epithelial carcinoma cell line T4Ps5 (18) was
generously provided by Drs. P Maddon and R. Axel (Columbia University, New York). This
line was constructed by transforming naturally adherant HeLa cells with the cloned gene
for CD4 and was shown to support the growth of HIV-1 (18). Thus, it formed a monolayer
that was suitable for detecting HIV-1 plaques. The cells were grown in the presence of 0.5
mg/ml Geneticin (G418 sulfate; Gibco Laboratories, Grand Island, NY) in complete medium
containing DME supplemented with 4.5 g/liter glucose and 15% heat-inactivated FCS, 100
U/ml penicillin, 100 p.g/ml streptomycin, and 2 mM glutamine. Uninduced cells expressed
surface CD4 on -15% of cells (as measured by cytofluorometry), which increased to 30%
after induction with epidermal growth factor (EGF)' (100 ng/ml) for 1 h. All assays were
done with induced cells, except as noted.
Sera.
￿
Human sera were obtained from asymptomatic donors who were discovered to be
seropositive by routine bloodbank screening. They were confirmed positive by demonstrating
reactivity to multiple bands on Western blot and were a gift of Dr. J. Wai-Kuo Shih of the
NIH Department of Transfusion Medicine. Normal sera were obtained from laboratory
workers, and three additional seracounted inthis group were falsepositives by ELISA testing
but were repeatedly Western blot negative over a period of 6 mo. Additional sera from pa-
tients with clinical AIDS were a gift of Dr. Robert Yarchoan of the NIH, and sera from pa-
tients with adult T cell leukemia, seropositive for HTLV-I, were a gift of Dr. Thomas Wald-
mann, NIH. Sera from patients with autoimmune diseases were a gift from Dr. Laurence
Rubin, University of Toronto Medical School.
Virus.
￿
H9 cells infected with the IIIB (4) and RFII (6) isolates of HIV-1 as well as the
NIHZ isolate of HIV-2 (19) were provided by Drs. Robert Gallo and Howard Streicher (Na-
tional Cancer Institute) and by Drs. Hiroaki Mitsuya and Sam Broder (NCI), and A3.01
cells (20) infected with Zaire-1 (Zl) (21) were provided by Dr. Thomas Folks (NCI). Virus
was passaged monthly by freshly infecting H9 cells, as confirmed by the appearance ofviral
p24 antigen in the culture supernatants (22). Infected H9 cells were irradiated (10,000 rad,
Cs137 irradiator) before use in the assay.
Virus-sped DNA Probe.
￿
The probewas a slightly truncated 9.2-kb fragment ofthe cloned
BH10 isolate of HIV-1 (4). It was s2p labeled with a nick translation kit from New England
Nuclear (Boston, MA), and purified on a Sephadex G50 spin column, giving a specific ac-
tivity of ti2 x 107 cpm/pg. As shown in Fig. 1, the probe could detect a dot containing the
amount of viral RNA in 5,000 infected H9 cells, but there was no background signal from
106 uninfected H9 cells. In subsequentexperiments, with acutely infected H9 cells, dots con-
taining as few as 1,000 infected cells were detectable.
PlaqueformingAssay.
￿
The assay can be divided into a virus growth step followed by a plaque
detection step (Fig. 2). CD4' HeLa cells were incubated for 1 h in the presence of 100 ng/ml
EGF (Collaborative Research, Lexington, MA). They were then washed and infected by in-
cubation with various dilutions of cell-free HIV-1 or with various numbers of infected H9
cells for 2 h at 37°. The cellswere plated in 5-cm diameter tissue culture dishes (3060; Costar,
Cambridge, MA) overnight in complete medium (without geneticin). The next day, the cul-
ture medium was replaced with an agarose overlay containing 4 ml of0.8% Seaplaque agarose
(Marine Colloids Inc., Rockland, ME) in complete medium. The cells in the culture dishes
were diluted ti1 :80 relative to confluence, and they grew to confluence in N7 d.
I Abbreviations used in this paper: EGF, epidermal growth factor; PFU, plaque-forming units; rCD4, recom-
binant soluble CD4.BERKOWER ET AL .
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Zones of viral infection on the monolayer were detected by DNA-RNA hybridization, by
a modification of the method of Villareal and Berg (23) . When the infected monolayer cells
reached confluence, the entire monolayer was transferred from plastic to nitrocellulose by
removing the agarose and pressing down discs of nitrocellulose paper saturated with 0.05 M
Tris-HCI, pH 7, and 0.15 M NaCl on the surface of the monolayer. When the discs were
lifted off the plastic, the entire cell monolayer came off with them . The cells were lysed by
placing the discs on a filter paper saturated with 6% formaldehyde in 6 x SSC and 50%
formamide, for 10 min at 65°, followed by 6 x SSC and 0.1% SDS, and then 6 x SSC at
room temperature . The discs were air dried and baked in a vacuum oven for 1 h at 80 °C .
After baking, the discs were washed in 6 x SSC and then prehybridized with a mix con-
taining 6 x SSC, 10% dextran sulfate, 5% Denhardt's Solution, 0.1% SDS, 0.1% Poly adeno-
sine (>100,000 mol wt), and 300 jug/ml boiled herring sperm DNA. After prehybridizing
4 h at 65 °C, the discs were hybridized with a 12P-labeled viral probe in fresh prehybridiza-
tion mix for 18 h at 65°. After hybridization, the filters were washed twice at 55 °C with
2 x SSC with 19o SDS, followed by 0.2 x SSC with 0 .1 9 Jo SDS at 50°C . The discs were then
dried and placed in a photographic cassette with x-ray film .
Detection ofNeutralizing Antibodies .
￿
A known titer ofvirus or virally infectedH9 cells con-
taining between 100 and 3,000 plaque forming units (PFU) ofHIV-1 was incubated for 2 h
at 37 °C in the presence of various dilutions ofserum from seropositive patients or immunized
rabbits in a final volume of 50 Etl . One-third or one-tenth of the surviving virus was used
to infect CD4+ HeLa cells during a further 2-h incubation, followed by the standard pla-
quing assay. The neutralizing titer was defined as the serum dilution giving a 509o reduction
in plaque number.
Results
Plaque Formation.
￿
Previous attempts at detecting HIV-1 plaques were stymiedby
the lack of an adherent monolayer cell able to support the growth of the virus and
by difficulty visualizing the cytopathic effects of the virus . We have now solved the
monolayerproblem by use of the genetically engineered CD4+ HeLa cell, provided
byMaddon and Axel (Columbia University, New York), which is naturally adherent
and has acquired the ability to support the growth ofHIV-1 (18). In addition, our
HIV-specific detection system is sufficiently sensitive to detect the amount of virus
in a single plaque. This was demonstrated by infecting monolayer cells with recom-
binant vaccinia virus vsc 25 (24) containing the env gene ofHIV-1 and by detecting
the lytic plaques with the '2P-labeled HIV-specific probe (not shown) .
We then used the hybridization method to detect infection of the CD4+ HeLa
monolayerbyHIV1 . After 7-10 d in culture, we detected discrete, macroscopic viral
plaques by hybridization, as shown in Fig . 3 . Several HIV isolates, representing nearly
the entire spectrum ofHIV-1 as well as one HIV-2 isolate, were tested . In spite of
differences in sequence (4-6, 19) and possibly in cytopathic effect, similar plaque
FIGURE 1 .
￿
Detection of viral
nucleic acid in infectedH9 cells.
Different numbers ofinfected or
uninfected cells were blotted
onto nitrocellulose paper and
viral nucleic acid was detected
by hybridization with a "P-la-
beled probe.1684
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Virus + Antibody
2 h at 37°
Add C04' Hela Cells
4h at 37 0 Infected Foci
on CD4' Monolayer
Lyse Cells
Hybridize
Bake
Expose Film
FIGURE 2. Method for developing HIV-1
plaques. Virus is grown on the CD4*
monolayer for 7 d . Discrete foci of infection
are detected by transferring the entire mono-
layer to nitrocellulose, followed by s cell lysis,
baking, and hybridization with a 2P-labeled
virus-specfic probe .
FIGURE 3 .
￿
DivergentHIV isolates, arranged according to their deduced evolutionary tree (25),
were detected as discrete plaques . The number ofPFU observed after infecting the monolayer
with virus from infected H9 cells were as follows : 63PFUfrom 300 IIIII-infected cells, 121 PFU
from 6,000 RFII-infected cells, 186 PFU from 1,000 Zl-infected cells, and 55 PFU from 1,500
HIV2-NIHZ-infected cells . Vertical branch lengths indicate extent ofgenetic divergence, as mea-
sured by the number of third codon substitutions (adapted from reference 25) . Strain Zaire-1
has been substituted for Zaire-3, which it resembles (21) .morphology was observed foreach isolate. In Fig. 3, different isolates are arranged
according to their deduced evolutionary tree, so that the vertical distance and the
number of branches between isolates indicate evolutionary divergence as deduced
from base substitutions in the envelope gene (25). Ifgenetic variation among HIV-1
isolates is the result of antibody-mediated natural selection, then pairwise compar-
isons ofvariants for antibody resistance should correlate with the number ofevolu-
tionary branch points between them (discussed below). The plaques were macro-
scopic, 0.5-1.5mm in size, andthe numberofPFUwas readilycounted bydisplaying
the exposed film over an x-ray view box. The number ofPFU was linearly propor-
tional to the input ofvirus up to at least 160 plaques per culture, and no plaques
were formed in the absence of virus or when a CD4- monolayer cell (CV-1 or
normal HeLa cells) was substituted for the CD4+ HeLa cell line. Thus, plaque for-
mation is the result ofviralgrowth onthe monolayeranddepends on the CD4 receptor
of the monolayer cells. Microscopic observation of the monolayers revealed some
giant cells, but, at the low multiplicity ofinfection used in this assay, there was no
consistent difference between the infected and uninfected CD4+ monolayer cells
with regard to cytopathic effects or syncytium formation.
Comparison ofthe plaquing assay with the previously available antigen capture
RIA (22) is shown in Fig. 4. There was an excellent correlation between PFU and
antigen release into the culture medium over a 25-fold range ofvirus input. This
enabled us to examine the effect of host cell activation on viral growth. It is well
known that T cell activation by mitogens can enhance the recovery of HIV-1 (2),
and a possible transcriptional mechanism involving the shared enhancer motifbe-
tween the HIV-1 long terminal repeat and the NFKB site oflymphocytes has been
proposed (26, 27), so we tested whether activation of CD4+ HeLa cells with EGF
would have a similar effect on the efficiency ofplaque formation. As shown in Fig.
4, activation of the monolayer cells gave increased numbers of PFU at each dose
of virus, and the production of viral antigen increased proportionately. However,
the slope ofPFUvs. antigen production remained the same, indicatingthat average
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FIGURE 4.
￿
Correlation ofPFUvs. antigen pro-
duction per culture, as measuredby antigen cap-
ture RIA (22). CD4' monolayer cells were in-
fected with 2.5 x 10 5 (circles), 5 x 104 (squares),
or 104(triangles) 11113-infected H9 cells. PFU and
viral antigen production were linearly propor-
tional overtheentire dose range, whetherthecells
were untreated(open symbols)or treatedwith EGF
(closed symbols).1686
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viral antigen production per plaque was unchanged by EGF activation . We con-
clude that EGF improves the plaquing efficiency, but it is still unclear whether this
works primarily by stimulating the host cell to produce more CD4 receptors (see
Materials and Methods) or by stimulating viral transcription .
Titration ofNeutralizing Antibodies .
￿
Sincethe number ofplaques is linearly propor-
tional to the input of cell-free virus, each plaque must result from infection by a
single virus . If double infections occurred, then the number of double infections
would increase with the second power of the input number of viruses . Inactivation
of even a few viruses would cause a corresponding reduction in PFUs, making this
assay highly sensitive to the effects of neutralizing antibodies .
For example, as shown in Fig. 5, serum from an asymptomatic seropositive pa-
FIGURE 5 . Antibody sensi-
tivity ofIIIB andRFII isolates .
H9 cells infected with either iso-
latewere incubated with various
dilutions ofa patient'sserum or
with an inactive control . The
surviving plaques were mea-
sured in the standard assay.
Counting the plaques directly
from the exposed negatives gave
the following numbers ofPFU
for IIIB, reading vertically: 140,
1, 9, 37, and108 (some ofwhich
were lost in printing) ; and for
RFII : 165, 7, 5, and 79 . The
1:1,200 dilution was not tested
on RFII .tient was titered against two divergent HIV-1 isolates, IIIB and RFII. For the IIIB
isolate, incubation with the 1 :40 and 1 :120 dilutions of serum gave nearly complete
inhibition of viral plaques. The 1 :400 dilution gave less neutralization, and there
was only a slight antibody effect at 1 :1,200. Essentially identical results were ob-
tained when the serumwas titered against RFII, including nearly total neutraliza-
tion at the first two dilutions, with partial viral breakthrough at 1 :400. The antibody
titer against both isolates was estimated at 1 :800, based on the dilution at which
half of the PFU survived. Normal serum had no effect on either isolate at the 1 :40
dilution. Thus, these two strains of HIV-1 are immunologically equivalent with re-
gard to the neutralizing antibodies present in this serum, in spite ofamino acid differ-
ences of217o in the envelope proteins. The fact that the neutralizing titer is the same
on both viruses also shows that the group-specific antibodies predominate over any
type-specific neutralizing antibodies that may be present.
Numerical results for HIV neutralization with the same serum are shown in Fig.
6, but this time comparing the titration of the serumagainst IIIB and Z1. The ratio
of surviving PFU divided by input PFU (V/Vo) is plotted against the antibody di-
lution used to treat the virus. Both isolates were neutralized 99.5% by the 1 :50 dilu-
tion ofantibodies, between 96 and 98% at 1 :120, and between 86 and 89% at 1 :400.
Once again, we obtained a neutralizing titerof 1 :800 for both viruses. Thus, in spite
ofhighly divergent envelope sequences, both IIIB and Zl are immunologically equiva-
lent with regard to these neutralizing antibodies.
Because antisera neutralized IIIB and RFII equally, we tested whether the anti-
bodies that neutralized both viruses were the same or different. To do this, another
patient's serum with high titer group-specific neutralizing antibodies was adsorbed
with recombinant viral envelope glycoproteins gp160 or gp41 or with core protein
p24 of the IIIB type. After adsorption with these proteins, the residual neutralizing
activity was measured on homologous HIS virus or on variant RFII virus. As shown
in Fig. 7, adsorption with IIIB envelope glycoprotein removed 90% ofthe neutralizing
activity against the homologous IIIB virus and 80-90% ofthe neutralizing activity
against the RFII variant. In contrast, adsorption with p24 or gp41 gave little or no
reduction in neutralizing activity against either virus. Thus, nearly all of the neu-
VNo
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FIGURE
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6.
￿
Antibody sensitivity of the IIIB and Zl iso-
lates. H9 cells infected with either isolate were incubated
for 2 h with the same patient's serum as in Fig. 5 or with
anormal control serum. The surviving fraction of virus is
V/Vo, where V are the number of PFU surviving in the
presence of antibody, and Vo are the number of PFU in
theabsenceofantibody. Vo (corrected fordilution) forthe
untreated controls were: 602 forIIIB and 936 for Zl. V/V.
wasdetermined in sextuplicate forIIIB, plottedas thearith-
metic mean t SD, and once for Z1. Normal serum had
no effect on either virus.1688
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tralizingantibodies inthis serumare directed against the envelope glycoprotein and
are group specific, since nearly all ofthe antibodies thatneutralize the RFII variant
are adsorbable by IIIB envelope glycoprotein, and the major neutralizing epitope
is shared by the envelopes of both viruses.
Clinical Results.
￿
Using this method, we have measured the neutralizing activity
of 14 sera from asymptomatic seropositive patients on the IIIB isolate (Fig. 8) and
11 sera from patients with clinical AIDS. As controls, we also tested 11 seronegative
p24
9P41
1 :40 1:120 1 :400
￿
1 :40 1:120 1:400
9p160
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FIGURE 7.
￿
Adsorption of HIV-1 neu-
tralizing antibodies by recombinant
viral proteins. HIV-1 IIIB envelope gly-
coproteins gp160 and gp41, and p24
core antigen, were expressedin Spodop-
ferafiugiperda cells infected with recom-
binant baculovirus (28). Patientserum
wasadsorbed with each cell-associated
protein, andthe residual neutralizing
activity wastested against11111or RFII
virusin thestandard assay. Theextent
of antibody adsorption by gp160 was
>32-fold and by p24 was eightfold as
measured by an ELISA using recom-
binant viral proteins. Vo was 110 for
IIIB and 144 for RFII.
FIGURE 8. Clinical summary. Each
patient's serum was assayed for neu-
tralizingactivity at 1:20and 1:200 di-
lutions. Symbolsare as follows: asymp-
tomaticseropositives (opencircles), AIDS
patients with Kaposi's sarcoma (closed
squares) or with opportunistic infections
(opensquares) autolrnmune patientswith
systemic lupus (closed circles); or with
rheumatoid arthritis or Sjogren's syn-
drome (opencirdes). Thepercent neutra-
lization of IIIB by the 1:200 dilution
ofeach serumis plottedlogarithmically
on they-axis and is calculated by the
formula: 100x (1VNo), where V are
thenumber ofPFU surviving andVo
are the number of PFU with no anti-
bodies added. Arithmetic means t SD
are indicated.
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<5normal sera, five sera from HTLV I-infected patients, and 12 sera from autoim-
mune patients. Each serumwas tested at the 1:20 and 1:200 dilutions, and the per-
cent neutralization at 1:200 is shown in Fig. 8. Sera from 11 normal controls gave
<12% neutralization ateither 1:20 or 1:200. In contrast, serafrom halfofthe asymp-
tomatic seropositive patients neutralized >50% at a dilution of 1:200. The median
neutralizing titer ofthese patients' sera was 1:200, and some patients had titers as
high as 1 :2,000 and 1:6,000 in subsequent assays. These titers exceed by >1 log the
highest titers detected by earlier assay methods (29-31), and the difference between
the seropositive patients and normal controls was highly significant (p < 0.0005).
Ofeleven patientswith clinicalAIDS, three offour withKaposi's sarcomahad levels
of neutralizing antibodies similar to those found in asymptomatic patients, while
sevenwith opportunistic infections had generally lowerlevels ofneutralizing antibodies.
Sera from 12 autoimmune patientswith systemic lupus, rheumatoid arthritis, or
Sj6gren's syndrome failed to neutralize HIV1, indicating that this is not simply an
autoimmune phenomenon mediated by antilymphocyte antibodies. The seraoffive
adult T cellleukemia patients with antibodies to HTLVI failed to neutralize HIV-1
ateither dilution, indicatingthat neutralization coulddistinguishbetweenthesetwo
members of the human T cell retrovirus family. However, when sera from seven
patients in the asymptomatic seropositive group were retested on a second HIV-1
isolate (RFII), theyall neutralized IIIB and RFII equally (oneofthese serais shown
in Fig. 5), indicatingthat theyall recognizeapredominant group-specific neutralizing
epitope for HIV1.
Extent andKinetics ofNeutralization.
￿
The neutralization assay provides useful in-
formation both at antibody dilutions causing 50% inactivation, which define the
titer, andat antibody excess, where thepercent ofvirus survivingprovides an upper
limit for thefrequency ofspontaneously occurringantibody-resistant variants in each
isolate. As shown in Figs. 5 and 6, both IIIB and Zl contained <1 resistant plaque
in 200, while RFII contained <1 in 100. In addition, the kinetics of inactivation
of IIIB were linear over the first two logs of inactivation (Fig. 9), indicating that
thelast 5% ofplaques to be inactivated were noless sensitivethan the first 5%, since
they were inactivated at the same rate. Thus, in spite ofextensive molecular varia-
tion (6, 32), antibody-resistant variants of HIV-1 are actually quite rare, and the
IIIB isolate is uniformly sensitive to neutralizing antibody.
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FIGURE 9.
￿
Inactivation kinetics of cell-associated virus. IIIB-infected
H9 cellswere incubatedwith patientantibodies at antibody excess (1 :20
dilution) for various times, washed, and added to the CD4' HeLa
monolayer cells for plaquing. The fraction of viruses remaining infec-
tious(VVo)wasplotted on alogscalevs. time, showing linear inactiva-
tion kinetics forup to 99% of the starting inoculum. Vo = 2,500 t 10
PFU (duplicates).1690
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FIGURE 10.
￿
Soluble recombinant CD4neutralizes HIV1. Increasing
doses of rCD4 (a gift of Dr. Daniel Capon, Genentech, Inc., South
San Francisco, CA)were incubated with cell-associatedvirus for 2 h
at 37°C followed by infecting the monolayer cellsin the presence of
theinhibitor foran additional 5 h. Recombinant CD4inhibited PFU
at concentrations of 1 ug/ml or higher.
Effect ofsoluble CD4.
￿
Recent reports havedemonstrated thatsoluble recombinant
CD4 can neutralize HIV-1 in vitro (12-14), as shown by the inhibition ofviral gene
expression. With the plaquing assay we could determine whether the antiviral effect
ofCD4 prevented the initial infection or occurred during subsequent steps of the
virus life cycle. As shown in Fig. 10, incubation ofvirus with soluble recombinant
CD4 for 2 h before infection ofthe monolayer cellsgave a markedreduction in PFU
at CD4 concentrations of 1 pg/ml or greater. Thus, CD4 inhibits the number of
infection events, perhaps by mimicry ofthe cellular receptor for HIV1, or by com-
petition with the receptor. These results also demonstrate that the plaquing assay
provides a sensitive measure ofviral inactivation, independent of the mechanism
of inactivation.
Discussion
Using the plaque reduction assay, we have found significant new evidence that
the human immune response to HIV-1 infection produces neutralizing antibodies
against a broad spectrum of HIV-1 isolates, rather than a narrow band of HIV-1
serotypes closely related to the infecting strain. These are the predominant neu-
tralizing antibodies elicited by infection and may play amajor role in the host-virus
interaction. Their frequent occurrence in nearly all infected patients implies that
the group-specificneutralizing epitope is shared by multiple HIV-1 strains, in spite
ofthe rapid mutation rateofHIV1. Ifsimilargroup-specificneutralizingantibodies
could be elicited by vaccination, humoral immunity couldplay a role in preventing
the spread of HIV1.
Group specificity is not an artifact ofour assay method, since neutralizing anti-
bodies from a gp160-immune rabbit were found to be type specific for the homolo-
gous HIV-1 isolate (data not shown). Neither is it simply the aggregate result of
multiple type-specific antibodiesinduced byinfection with an unknown HIV-1 strain,
since absorption studies with arecombinant HIV-1 envelopeglycoprotein gp160 from
one isolate indicate that the same antibodies neutralize both the IIIB and RFII iso-
lates. Finally, virus neutralization in our assay is specific for HIV-1, as shown by
the failure ofserafrom HTLV I-infectedpatients to inactivate HIV1, despite their
relatedness by Western blot (33).
The mechanism ofviral neutralization by these antibodies is currently unclear,
although they are mostlikely directed against conserved regions ofgp160. Absorp-
tion experiments with recombinant viral proteins are in progress to map the loca-
tionoftheseeptitopes. Essential functionsofgp160include bindingtothe CD4receptor
(18, 34), penetrationofcell membranes viathefusion peptide(35), orviraluncoating.BERKOWER ET AL.
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Thus, neutralizing antibodies that bind to critical regions ofthe viral envelope and
interfere with these functions could block infection. For example, ifthey act on the
CD4-bindingsite, they could mimicsoluble CD4 and inactivate HIV-1 by competi-
tivebindingtotheC134-binding sites, whichpresumes nearsaturation levels ofbinding,
or by triggering a conformational change in the virus that may require binding to
only a fewCD4receptor sitespervirion. The latter mechanismis foundin poliovirus,
where binding of a few neutralizing antibodies per virion inactivates the virus by
triggering a conformational change detectable as a shift in the isoelectric point of
the virus (36).
Why should a major neutralizing epitope of HIV be conserved in a virus that
is known to mutate so rapidly? This is not so surprising when we consider other
structural features and functions ofgp120 that are conserved amongall isolates. The
gp120 glycoprotein isknown tohave five conservedregionsinterspersed amongvari-
able regions (37). Also conserved are the 20 cystines for disulfide bonds, important
glycosylation sites (38), and the gp120-gp41 proteolytic processingsite. In eachvariant,
the gp120function ofCD4binding is preserved, andtheyremain sensitive toinacti-
vation by soluble CD4 (15). Also, gp120 retains its other physiologic functions in
virus assembly, membrane fusion, anduncoating inside thecell. Theseessentialfunc-
tions place constraints on the virus that may limit the range of viable mutations
in gp120 to some sites and not others. Since neutralizing antibodies could bind a
site with an essential function, antibody escape mutations at this site may be lethal
for the virus.
Anotherexplanation for thefailure ofgenetically divergent isolates todevelop an-
tibody resistance couldbethetendency ofHIV-1 tomutate inthe absence ofantibody-
mediated selection. Mutation is a random process, limited only by the nonviability
ofmutations affecting essential viral functions. But these mutants only serve as the
substrate forimmunologicselection ofantibody-resistant variants (39), whichoccurs
whenthe virus triestogrow in the presenceofneutralizing antibodies. Then, a slight
growth disadvantage due to the mutation could be overcome by the selective advan-
tage of antibody escape, leading to natural selection of antibody-resistant variants
from all the available mutants. However, since HIV-1 rarely if ever reinfects previ-
ously immune individuals (40), and since it becomes an integrated provirus soon
after infection (41), before the immune responsehas peaked (42), it is not surprising
that numerous molecular variants of HIV-1 can be generated randomly without
evolving toward antibody resistance. This hypothesis is supported by the evidence
that IIIB and Z1 have progressed through a minimum ofthree evolutionary branch
points since they diverged from a presumed common ancestor (Fig. 3) without de-
veloping antibody resistance. These branch points may have greater biologic sig-
nificance thantheoverall number ofamino acid substitutions, sinceantibody escape
is usually due to point mutations (43), independent ofthe overall number ofamino
acid substitutions. Ifthis hypothesis is correct, then the group-specific neutralizing
epitope would be an ideal target for vaccine-induced antibodies, which would con-
front susceptible viruses of many types as soon as possible after infection, before
they could hide as provirus or escape through mutation.
Further evidence oftheinability ofHIV-1 toescape from group specificneutralizing
antibodies is therarity ofantibody-resistant variants amongthe three HIV-1 isolates
tested. With the plaquing assay, we have analyzed hundreds ofPFU at a time, in1692
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order to detect rare variants. However, the nearly complete inactivation ofPFU in
the presence ofexcess neutralizing antibodies (demonstrated in Fig. 5 and 6) indi-
cated that<0.5% ofviruses in each isolatewere potentiallyantibody resistant. Since
this includes some viruses that survived due to the kinetics of neutralization (Fig.
9),theactual frequencyofresistant variants maybemuch lower. This low frequency
suggests that each isolatehasnot accumulated escape mutants at the group-specific
neutralizingepitope, even after multiple rounds ofviral replication in the host and
unselected infections in culture. Perhaps mutations at this site produced defective
virus, so that few or novariants were available for antibody selection. Alternatively,
these mutants may bepresent in very low frequency, requiring rounds ofinfection
under selectiveconditions in thepresence ofantibodiesfor enrichment to detectable
levels.
Our results with patient sera suggest that group-specific neutralizing antibodies
are produced by nearly all infected patients, suggesting that the epitope is widely
shared amongthe HIV-1 isolates that infected our patients and is broadly immuno-
genicduring infection. The general correlation betweenapatient's titer ofneutralizing
antibodies and his stage ofdisease, wheather asymptomatic seropositive, Kaposi's
sarcoma, or AIDS with opportunistic infection, is consistent with some antiviral
effect due to neutralizing antibodies, although it could also be the result ofhis clin-
ical condition. The predictive value ofhigh titered neutralizing antibodies is cur-
rently unknown, since most infected patients will eventually progress to clinical im-
munodeficiency in spite ofhaving neutralizing antibodies. However, the prolonged
duration of the asymptomatic infected state (44) suggests that the host's immune
response may alter the course ofinfection. In addition, the rarity ofreinfection (40)
suggests that something about the host's immune response, quite possibly group-
specific neutralizing antibodies, makes him resistant to second infections, even by
divergentisolates. In thatcase, antibodiesto the group-specific neutralizingepitope,
if elicited by a vaccine antigen before infection, might help prevent the first infec-
tion. Thebroad spectrum anti-HIV-1 effect ofantibodies to aconserved epitope im-
plies interference withanessentialand immutable viral function, which, ifattacked
early in the infection, might abort the infection. Thus, the ability to induce group-
specific antibodies may serve as a biologically relevant marker in the search for a
suitable vaccine antigen.
Summary
HIVI is knownto show a highdegree ofgenetic diversity, whichmayhave major
implications for disease pathogenesis and prevention. Ifevery divergent isolate rep-
resented a distinct serotype, then effective vaccination might be impossible. How-
ever, usingasensitivenew plaque-forming assay forHIV-1, we havefound thatmost
infected patients make neutralizing antibodies, predominantly to a group-specific
epitope shared among three highly divergent isolates. This epitope persists among
divergent isolatesand rarely mutates, despitetherapid overallmutation rateofHIV1,
suggesting thatit mayparticipate in an essentialviral function. These findings, plus
the rarity of reinfections among these patients, suggest that HIV-1 may be more
susceptibleto a vaccine strategy based on a group-specific neutralizing epitopethan
was previously suspected.BERKOWER ET AL.
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